Day: June 25, 2023

Press ReleaseJune 25, 2023 – N° 14 Fabrice Brégier is appointed Chairmanof SCOR’s Board of Directors SCOR’s Board of Directors, which met on June 25, 2023, has unanimously decided to appoint Fabrice Brégier non-executive Chairman, with immediate effect. This decision was made on the unanimous recommendation of the Nomination Committee, at the conclusion of a demanding and rigorous succession process initiated in spring 2022. Over the months since the process began, the Nomination Committee, assisted by the international recruitment firm Egon Zehnder, has met on numerous occasions to define the search criteria for the future Chairman, to select first-rate individuals who could match the expected profile, and finally to meet the candidates most likely to take the helm of the Board. The Committee, chaired by Adrien Couret, ultimately...

  ALTUVIIIOTM late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosingXTEND-Kids data confirm the efficacy and safety profile of ALTUVIIIO with simple, weekly 50 IU/kg dosing for both adults and children ALTUVIIIO’s expanding evidence of a first and best-in-class profile supports Sanofi’s commitment to delivering paradigm shifting therapies for Rare DiseasesParis, June 25, 2023. Pivotal data from the Phase 3 XTEND-Kids study evaluating ALTUVIIIOTM [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] once-weekly prophylaxis, a first-in-class, high-sustained factor VIII replacement therapy, in previously treated patients younger than 12 years of age with severe hemophilia A were presented today in a late-breaking session at the Annual Meeting of...

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativaFirst placebo-controlled randomized trial in HS to report positive topline results using HiSCR75 as the primary endpoint Primary endpoint HiSCR75 met with 29 percentage points (ppt) delta vs placebo (p=0.0002) at week 12, setting a new bar in HS HiSCR50 met with 38 ppt delta vs placebo (p

                                                          Communiqué vidéo de Patrick MARCHE et Bernard VOISIN NEOLIFE® (Euronext Growth : FR0011636083 – ALNLF), (la « Société ») annonce partager un communiqué vidéo de Patrick MARCHE et Bernard VOISIN, respectivement Président du Conseil de Surveillance et Président du Directoire de la Société. Communiqué vidéo Patrick MARCHE et Bernard VOISIN La Société rappelle toujours se tenir à disposition des actionnaires via l’adresse mail investors@neolife.fr pour répondre à leurs questions en amont de l’assemblée générale du 26 juin. CONTACTNEOLIFE®investors@neolife.frAttachmentCP NEOLIFE 25 JUIN 2023 – Vidéo Direction